The human papillomavirus (HPV) vaccine protects against human papillomavirus (HPV) infections. HPV is a group of over 200 related viruses, over 40 of which are transmitted through direct sexual contact. Among these, two forms of HPV cause genital lumps and some other types of HPV lead to cancers such as anal, cervical, penile, oropharyngeal, vulvar, and vaginal cancers. Similar to other vaccines that protect against viral infections, HPV vaccines help the body develop antibodies that can fight HPV and protect other cells in the body from infection.
Genital HPV infection is the most common sexually transmitted infection, found in nearly 9-13% of the world’s population, and about 6 million people become infected each year. The likelihood of contracting HPV is usually high in adolescence or young adulthood. HPV infection is contemplated to contribute nearly 100% of cervical cancers and about 80% of anal cancers and 40-60% of vaginal, penile, and vulvar cancers. Two prophylactic HPV vaccines are currently commercially available and both are being developed from purified L1 structural proteins.
Why are HPV vaccines so popular?
According to the Centers for Disease Control and Prevention (CDC), HPV is the most common sexually transmitted infection in the United States and has been linked to health problems such as genital warts and cancer. The World Health Organization (WHO) recommends vaccinating girls 9-14 years of age with the HPV vaccine when most of them are not engaging in sexual activities to prevent contracting HPV.
Growing people’s awareness of HPV infections and the increasing incidence of HPV disease in the oropharynx, anal and genital areas around the world are the main drivers driving the demand for HPV vaccines. In recent years, both governments and private institutions have taken several initiatives to ensure the availability of HPV vaccines in order to contain the spread of the virus.
How has the COVID-19 pandemic affected the human papillomavirus vaccine industry?
With the outbreak of the COVID-19 pandemic, the demand for HPV vaccines has increased, which is having a positive impact on the vaccine industry against human papillomaviruses. According to a research report by Research Dive, the Global Human Papillomavirus Vaccine Market is expected to generate revenue of $ 9,283.6 million by 2027, growing at a CAGR of 12.0% from 2020 to 2027. During the pandemic, governments in many regions imposed strict lockdowns and introduced multiple rules to help contain the spread of the deadly COVID-19 disease. However, regardless of lockdown restrictions and strict government regulations, the number of COVID-19 infected patients rose and most health care workers had to perform their duties at risk of death. As a result, there was an urgent need to develop an effective vaccine, which is why various pharmaceutical companies that make HPV vaccines are investing heavily in the research and development of the coronavirus vaccine along with the HPV vaccine.
Key facts and developments related to the human papillomavirus vaccine
In recent years, several researchers and vaccine manufacturers have taken various initiatives such as novel developments and research, strategic partnerships, collaborations and much more to develop vaccines against HPV. For example, in November 2020 the World Health Organization (WHO) launched a “Cervical Cancer Eradication Strategy” to encourage all nations to band together and accelerate disease elimination with their tripartite strategy – 70% screening coverage, 90% HPV vaccination protection and 90% access to cervical cancer and cancer treatment.
In addition, Pregna International Ltd., a leading contraceptive solutions company, upgraded its status as a leading women’s health organization in January 2021 by introducing an innovative device called CryoPop to fight cervical cancer.
In addition, according to a new study published in Acta Obstetricia et Gynecologica Scandinavica, a peer-reviewed medical journal in gynecology, female urology, gynecological oncology, and fertility, the HPV vaccine may reduce the likelihood of high-grade cervical intraepithelial neoplasia (CIN) reduce. a condition that can cause cervical cancer.
In June 2020, Merck, known as MSD, a pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved an expanded indication for GARDASIL 9 for the prevention of oropharyngeal and other head and neck cancers issued by HPV types 58, 52, 45, 33, 31, 18 and 16..
Also, researchers are currently investigating whether a single dose of the HPV vaccine can be effective. A randomized clinical trial is currently being conducted in Costa Rica to determine whether a single dose of the HPV vaccine is sufficient to protect against HPV infection.
Future scope of human papillomavirus vaccine industry
As awareness of HPV infection prevention rises, so does the demand for HPV vaccinations, which is fueling the growth of the human papillomavirus vaccine industry worldwide. In addition, growing research and development activities to develop effective HPV vaccines are driving the growth of the industry. As a final point, the global human papillomavirus vaccine industry is about to reach new heights with the development of more efficient vaccines to protect the world from human papillomaviruses.
Reference link: https://www.researchdive.com/8339/Anlyst-Review/human-papillomavirus-vaccine-market
Mr. Abhishek Paliwal
30 Wall Street, 8th floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
Toll Free: +1 -888-961-4454
Email: [email protected]
Follow us on: https://industrialresearchworld.blogspot.com/